Display options
Cite
Quek L, Ferguson P, Metzner M, et al. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2016;1(3):193-204doi: 10.1182/bloodadvances.2016000760.
Quek, L., Ferguson, P., Metzner, M., Ahmed, I., Kennedy, A., Garnett, C., Jeffries, S., Walter, C., Piechocki, K., Timbs, A., Danby, R., Raghavan, M., Peniket, A., Griffiths, M., Bacon, A., Ward, J., Wheatley, K., Vyas, P., & Craddock, C. (2016). Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood advances, 1(3), 193-204. https://doi.org/10.1182/bloodadvances.2016000760
Quek, Lynn, et al. "Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia." Blood advances vol. 1,3 (2016): 193-204. doi: https://doi.org/10.1182/bloodadvances.2016000760
Quek L, Ferguson P, Metzner M, Ahmed I, Kennedy A, Garnett C, Jeffries S, Walter C, Piechocki K, Timbs A, Danby R, Raghavan M, Peniket A, Griffiths M, Bacon A, Ward J, Wheatley K, Vyas P, Craddock C. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2016 Dec 14;1(3):193-204. doi: 10.1182/bloodadvances.2016000760. eCollection 2016 Dec 27. PMID: 29296935; PMCID: PMC5737177.
Copy Download .nbib Format: NLM
Share it on

Blood Adv. 2016 Dec 14;1(3):193-204. doi: 10.1182/bloodadvances.2016000760. eCollection 2016 Dec 27.

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

Blood advances

Lynn Quek, Paul Ferguson, Marlen Metzner, Ikhlaaq Ahmed, Alison Kennedy, Catherine Garnett, Sally Jeffries, Claudia Walter, Kim Piechocki, Adele Timbs, Robert Danby, Manoj Raghavan, Andrew Peniket, Mike Griffiths, Andrew Bacon, Janice Ward, Keith Wheatley, Paresh Vyas, Charles Craddock

Affiliations

  1. Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  2. Department of Haematology, Oxford University Hospitals Foundation NHS Trust, Oxford, United Kingdom.
  3. National Institute for Health Research Biomedical Research Center Blood Theme, Oxford University Hospital, Oxford, United Kingdom.
  4. Centre for Clinical Haematology, Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  5. Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  6. West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital, NHS Foundation Trust, Birmingham, United Kingdom; and.
  7. Cytogenetics Laboratories, and.
  8. Oxford Biomedical Research Centre Molecular Diagnostics Laboratory, Oxford University Hospitals Foundation NHS Trust, Oxford, United Kingdom.

PMID: 29296935 PMCID: PMC5737177 DOI: 10.1182/bloodadvances.2016000760

Abstract

Disease relapse is the major cause of treatment failure after allogeneic stem cell transplantation (allo-SCT) in acute myeloid leukemia (AML). To identify AML-associated genes prognostic of AML relapse post-allo-SCT, we resequenced 35 genes in 113 adults at diagnosis, 49 of whom relapsed. Two hundred sixty-two mutations were detected in 102/113 (90%) patients. An increased risk of relapse was observed in patients with mutations in

Conflict of interest statement

Conflicts-of-interest disclosure: The authors declare no competing financial interests.

References

  1. J Exp Med. 2016 Jul 25;213(8):1513-35 - PubMed
  2. Leukemia. 2012 Mar;26(3):381-9 - PubMed
  3. Cancer Cell. 2014 Mar 17;25(3):379-92 - PubMed
  4. J Mol Diagn. 2013 Jan;15(1):81-93 - PubMed
  5. Sci Transl Med. 2012 Aug 29;4(149):149ra118 - PubMed
  6. Am J Hematol. 2015 Aug;90(8):732-6 - PubMed
  7. Eur J Haematol. 2014 Jun;92(6):471-7 - PubMed
  8. Haematologica. 2010 Jun;95(6):989-95 - PubMed
  9. Genome Res. 2011 Jun;21(6):936-9 - PubMed
  10. Blood. 2015 Oct 22;126(17):2062-9 - PubMed
  11. Blood. 2016 Jan 7;127(1):29-41 - PubMed
  12. Biol Blood Marrow Transplant. 2015 Feb;21(2):373-8 - PubMed
  13. N Engl J Med. 2014 Dec 25;371(26):2477-87 - PubMed
  14. Leukemia. 2015 Apr;29(4):988-91 - PubMed
  15. Blood. 2015 Feb 26;125(9):1367-76 - PubMed
  16. Genome Res. 2010 Sep;20(9):1297-303 - PubMed
  17. N Engl J Med. 2016 Feb 4;374(5):422-33 - PubMed
  18. Nature. 2015 Feb 26;518(7540):552-555 - PubMed
  19. Leukemia. 2013 Apr;27(5):1028-36 - PubMed
  20. N Engl J Med. 2012 Mar 22;366(12):1079-89 - PubMed
  21. Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2548-53 - PubMed
  22. Biol Blood Marrow Transplant. 2015 Mar;21(3):454-9 - PubMed
  23. Oncotarget. 2016 May 24;7(21):30492-503 - PubMed
  24. Cancer Genet Cytogenet. 2010 Apr 15;198(2):135-43 - PubMed
  25. N Engl J Med. 2013 May 30;368(22):2059-74 - PubMed
  26. Cancer. 2012 May 15;118(10):2665-73 - PubMed
  27. Cancer Cell. 2010 Dec 14;18(6):553-67 - PubMed
  28. Ann Hematol. 2015 Nov;94(11):1899-905 - PubMed
  29. Leukemia. 2012 Nov;26(11):2353-9 - PubMed
  30. N Engl J Med. 2016 Jun 9;374(23):2209-2221 - PubMed
  31. J Clin Oncol. 2007 Nov 1;25(31):4938-45 - PubMed
  32. Nature. 2014 Feb 20;506(7488):328-33 - PubMed
  33. Biol Blood Marrow Transplant. 2010 Dec;16(12):1649-57 - PubMed
  34. Biol Blood Marrow Transplant. 2016 Feb;22(2):385-390 - PubMed
  35. Blood. 2010 Jul 22;116(3):354-65 - PubMed
  36. Ann Hematol. 2016 Mar;95(4):625-35 - PubMed
  37. Bioinformatics. 2009 Sep 1;25(17):2283-5 - PubMed
  38. N Engl J Med. 2014 Dec 25;371(26):2488-98 - PubMed
  39. N Engl J Med. 2016 Jul 14;375(2):143-53 - PubMed
  40. Blood. 2013 Jul 4;122(1):100-8 - PubMed
  41. Best Pract Res Clin Haematol. 2009 Dec;22(4):543-50 - PubMed
  42. Biol Blood Marrow Transplant. 2016 Nov;22(11):1961-1967 - PubMed
  43. Nature. 2012 Jan 11;481(7382):506-10 - PubMed

Publication Types

Grant support